Starting Out in the Pharma Industry

Starting Out in the Pharma Industry

Author: C. Harrison

Publisher: Createspace Independent Publishing Platform

Published: 2017-01-22

Total Pages: 122

ISBN-13: 9781542559683

DOWNLOAD EBOOK

Bored of academia? Sick of publish-or-perish and the grant-chasing treadmill? You've probably thought about building a career in the pharmaceutical industry, only to find a confusing world of unfamiliar terminology, requirements, and job descriptions. This book explains the many complexities of the pharmaceutical industry: the processes, the expectations, the skills you need to know and the careers you can enter - all laid out in an informative and jargon-free manner. For those who have started or want to start in the pharmaceutical industry, this book is a vital resource. What does it include? - An introduction to the entire drug development and manufacturing process. We examine how a drug goes from chemical entity to a final pharmaceutical; how drug batches are made, checked, and released to the market; we look at the marketing process, pharmacovigilance, and how processes change over time. - Industry expectations. We look at the knowledge you should learn during the first few weeks and months, attributes you should be cultivating, and how to work effectively with your manager. - Industry skills you need to succeed. We cover skills such as effective communication in all its forms, how to attend and run a meeting; how to organise information, how to cope with the sudden demands on your time and how to plan and execute projects succesfully. - Starting and building your pharmaceutical career. We describe the most common entry roles taken by life scientists entering industry and how you can develop your career beyond that initial step. - Finally our terminology list helps explain the multitude of pharmaceutical terms which you will come across in your career.


Careers with the Pharmaceutical Industry

Careers with the Pharmaceutical Industry

Author: Peter D. Stonier

Publisher: John Wiley & Sons

Published: 2003-05-07

Total Pages: 380

ISBN-13: 9780470843284

DOWNLOAD EBOOK

In recent years, many factors have combined to change the operating environment of the international pharmaceutical industry leading to greater specialisation and sophistication. This new edition will give an update of the different opportunities in drug discovery and development and the scientific, medical or other specialist training needed to accomplish them. The scope of this edition has been broadened to encompass all major roles, including marketing and sales.


Business Development for the Biotechnology and Pharmaceutical Industry

Business Development for the Biotechnology and Pharmaceutical Industry

Author: Martin Austin

Publisher: CRC Press

Published: 2016-04-08

Total Pages: 202

ISBN-13: 1317170598

DOWNLOAD EBOOK

Business Development in the biotechnology and pharmaceutical industries accounts for over $5 billion in licensing deal value per year and much more than that in the value of mergers and acquisitions. Transactions range from licences to patented academic research, to product developments as licences, joint ventures and acquisition of intellectual property rights, and on to collaborations in development and marketing, locally or across the globe. Asset sales, mergers and corporate takeovers are also a part of the business development remit. The scope of the job can be immense, spanning the life-cycle of products from the earliest levels of research to the disposal of residual marketing rights, involving legal regulatory manufacturing, clinical development, sales and marketing and financial aspects. The knowledge and skills required of practitioners must be similarly broad, yet the availability of information for developing a career in business development is sparse. Martin Austin's highly practical guide spans the complete process and is based on his 30 years of experience in the industry and the well-established training programme that he has developed and delivers to pharmaceutical executives from across the world.


The Billion-Dollar Molecule

The Billion-Dollar Molecule

Author: Barry Werth

Publisher: Simon and Schuster

Published: 2013-08-20

Total Pages: 480

ISBN-13: 143912681X

DOWNLOAD EBOOK

Join journalist Barry Werth as he pulls back the curtain on Vertex, a start-up pharmaceutical company, and witness firsthand the intense drama being played out in the pioneering and hugely profitable field of drug research. Founded by Joshua Boger, a dynamic Harvard- and Merck-trained scientific whiz kid, Vertex is dedicated to designing—atom by atom—both a new life-saving immunosuppressant drug, and a drug to combat the virus that causes AIDS. You will be hooked from start to finish, as you go from the labs, where obsessive, fiercely competitive scientists struggle for a breakthrough, to Wall Street, where the wheeling and dealing takes on a life of its own, as Boger courts investors and finally decides to take Vertex public. Here is a fascinating no-holds-barred account of the business of science, which includes an updated epilogue about the most recent developments in the quest for a drug to cure AIDS.


Marketing Planning for the Pharmaceutical Industry

Marketing Planning for the Pharmaceutical Industry

Author: John Lidstone

Publisher: Taylor & Francis

Published: 2017-07-05

Total Pages: 169

ISBN-13: 1351919768

DOWNLOAD EBOOK

Marketing in the pharmaceutical and healthcare sector requires a particular set of skills; its intricacies mean planning is an essential prerequisite. The marketing planning system described in this book has been designed to enable marketing and product executives to produce a plan which serves as a dynamic management tool which will help them to get from where they are now to where they want to be next year and thereafter. Now in its second edition, this bestselling book has become the standard text for all product managers, marketing managers and directors working in this demanding industry. John Lidstone and Janice MacLennan have updated the book to embrace best current practice. A new orientation to external analysis and a reworking of the application of SWOT analysis, along with fresh material on sales forecasting and strategy implementation, bring the book up to date with current thinking and industry trends. Marketing Planning for the Pharmaceutical Industry is based on real life experience built up over many years. Each chapter takes the reader through the sequential stages of planning so that by the end they will be able to produce a practical plan ready for implementation. It is the only book of this type which tailors marketing to those working in the sector and as such is a unique, invaluable and indispensable resource.


Bad Pharma

Bad Pharma

Author: Ben Goldacre

Publisher: Macmillan

Published: 2014-04

Total Pages: 479

ISBN-13: 0865478066

DOWNLOAD EBOOK

Originally published in 2012, revised edition published in 2013, by Fourth Estate, Great Britain; Published in the United States in 2012, revised edition also, by Faber and Faber, Inc.


Pharma

Pharma

Author: Gerald Posner

Publisher: Simon and Schuster

Published: 2020-03-10

Total Pages: 816

ISBN-13: 1501152041

DOWNLOAD EBOOK

Award-winning journalist and New York Times bestselling author Gerald Posner reveals the heroes and villains of the trillion-dollar-a-year pharmaceutical industry and delivers “a withering and encyclopedic indictment of a drug industry that often seems to prioritize profits over patients (The New York Times Book Review). Pharmaceutical breakthroughs such as anti­biotics and vaccines rank among some of the greatest advancements in human history. Yet exorbitant prices for life-saving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on pre­scription opioids have caused many to lose faith in drug companies. Now, Americans are demanding a national reckoning with a monolithic industry. “Gerald’s dogged reporting, sets Pharma apart from all books on this subject” (The Washington Standard) as we are introduced to brilliant scientists, incorruptible government regulators, and brave whistleblowers facing off against company exec­utives often blinded by greed. A business that profits from treating ills can create far deadlier problems than it cures. Addictive products are part of the industry’s DNA, from the days when corner drugstores sold morphine, heroin, and cocaine, to the past two decades of dangerously overprescribed opioids. Pharma also uncovers the real story of the Sacklers, the family that became one of America’s wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the center of the opioid crisis. Relying on thousands of pages of government and corporate archives, dozens of hours of interviews with insiders, and previously classified FBI files, Posner exposes the secrets of the Sacklers’ rise to power—revelations that have long been buried under a byzantine web of interlocking companies with ever-changing names and hidden owners. The unexpected twists and turns of the Sackler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. “Explosively, even addictively, readable” (Booklist, starred review), Pharma reveals how and why American drug com­panies have put earnings ahead of patients.


Research and Development in the Pharmaceutical Industry (A CBO Study)

Research and Development in the Pharmaceutical Industry (A CBO Study)

Author: Congressional Budget Office

Publisher: Lulu.com

Published: 2013-06-09

Total Pages: 65

ISBN-13: 1304121445

DOWNLOAD EBOOK

Perceptions that the pace of new-drug development has slowed and that the pharmaceutical industry is highly profitable have sparked concerns that significant problems loom for future drug development. This Congressional Budget Office (CBO) study-prepared at the request of the Senate Majority Leader-reviews basic facts about the drug industry's recent spending on research and development (R&D) and its output of new drugs. The study also examines issues relating to the costs of R&D, the federal government's role in pharmaceutical research, the performance of the pharmaceutical industry in developing innovative drugs, and the role of expected profits in private firms' decisions about investing in drug R&D. In keeping with CBO's mandate to provide objective, impartial analysis, the study makes no recommendations. David H. Austin prepared this report under the supervision of Joseph Kile and David Moore. Colin Baker provided valuable consultation...